Summary
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
History
Axogen, Inc. was founded in 2004 with the goal of providing effective technologies to treat peripheral nerve injuries. We provide surgeons with products that enable them to repair and regenerate nerves. Our proprietary porcine tissue-based product, NeuroShield®, is used to help nerve regeneration in the body.
Mission
At Axogen, our mission is to provide the finest nerve repair and regeneration products to healthcare professionals to help improve their patient's quality of life.
Vision
Our vision is to develop and commercialize innovative surgical solutions that enable repair and regeneration of peripheral nerves, providing a healthier life for patients living with the physical and emotional challenges of nerve damage.
Key Team
Mr. Bradley L. Ottinger J.D. (Gen. Counsel & Chief Compliance Officer)
Mr. Gregory Davault (VP of Marketing)
Mr. Angelo G. Scopelianos Ph.D. (Chief R&D Officer)
Mr. Michael Donovan (VP of Operations)
Ms. Doris Quackenbush (VP of Sales)
Ed Joyce (Director of Investor Relations)
Ms. Isabelle Billet (Chief Strategy & Bus. Devel. Officer)
Recognition and Awards
Axogen has been awarded with various awards from leading medical organizations, including the Biomedical Engineering Society’s Emerging Technologies Award, and most recently, the 2017 IFA Medical Device of the Year.
References